ReviewDrug design, development and therapy2026
Anti-Inflammatory Properties of Agarwood (Aquilaria Spp.): An Integrated Review of Phytochemistry, Molecular Mechanisms, and Therapeutic Applications.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Agarwood, the aromatic resinous heartwood derived from Aquilaria and Gyrinops species, represents a promising natural resource for anti-inflammatory drug development. This comprehensive review synthesizes current scientific understanding of agarwood's anti-inflammatory properties, bridging traditional medicinal applications with modern pharmacological validation. The review examines the phytochemical foundations of bioactivity, focusing on sesquiterpenoids and 2-(2-phenylethyl) chromones (PECs) as principal bioactive constituents. We elucidate multi-target molecular mechanisms through which these compounds modulate inflammatory responses, primarily via inhibition of nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) pathways, along with emerging targets including the NLRP3 inflammasome. Comprehensive analysis of preclinical evidence from both in vitro and in vivo models demonstrates agarwood's efficacy across diverse inflammatory conditions, including gastrointestinal, hepatic, and neurological inflammation. Critical factors influencing therapeutic application, including phytochemical variability and bioavailability challenges addressed through advanced drug delivery systems, are systematically examined. Despite compelling preclinical data, significant translational gaps exist due to the absence of human clinical trials. This review identifies major challenges in standardization, sustainability, and clinical validation while proposing future research directions to advance agarwood-based therapeutics from traditional remedies to evidence-based medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.